» Articles » PMID: 8963728

Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment Effects and Relation to Coronary Angiographic Progression

Overview
Date 1996 May 1
PMID 8963728
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence suggests that triglyceride-rich lipoproteins contribute to coronary artery disease. Using data from the Monitored Atherosclerosis Regression Study, an angiographic trial of middle-aged men and women randomized to lovastatin or placebo, we investigated relationships between lipoprotein subclasses and progression of coronary artery atherosclerosis. Coronary artery lesion progression was determined by quantitative coronary angiography in low-grade ( < 50% diameter stenosis), high-grade ( > or = 50% diameter stenosis), and all coronary artery lesions in 220 baseline/2-year angiogram pairs. Analytical ultracentrifugation was used to measure lipoprotein masses that were statistically evaluated for treatment group differences and relationships to progression of coronary artery atherosclerosis. All low density lipoprotein (LDL), intermediate density lipoprotein (IDL), and very low density lipoprotein (VLDL) masses were significantly lowered and all high density lipoprotein (HDL) masses were significantly raised with lovastatin therapy. The mass of smallest LDL (Svedberg flotation rate [Sf] 0 to 3), IDL (Sf 12 to 20), all VLDL subclasses (Sf 20 to 60, Sf 60 to 100, and Sf 100 to 400), and peak LDL flotation rate were significantly related to the progression of coronary artery lesions, specifically low-grade lesions. Greater baseline levels of HDL3, were related to a lower likelihood of coronary artery lesion progression. In multivariate analyses, small VLDL (Sf 20 to 60) and HDL3 mass were the most important correlates of coronary artery lesion progression. These results provide further evidence for the importance of triglyceride-rich lipoproteins in the progression of coronary artery disease. In addition, these results present new evidence for the possible protective role of HDL3 in the progression of coronary artery lesions. More specific information on coronary artery lesion progression may be obtained through the study of specific apolipoprotein B-containing lipoproteins.

Citing Articles

Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women.

Sriprasert I, Kim S, Mohammed I, Kono N, Karim R, Allayee H J Clin Endocrinol Metab. 2024; 110(2):e301-e309.

PMID: 38547457 PMC: 11747678. DOI: 10.1210/clinem/dgae171.


Bee Products as Interesting Natural Agents for the Prevention and Treatment of Common Cardiovascular Diseases.

Olas B Nutrients. 2022; 14(11).

PMID: 35684067 PMC: 9182958. DOI: 10.3390/nu14112267.


Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels.

Superko H, Garrett B Biomedicines. 2022; 10(4).

PMID: 35453579 PMC: 9025822. DOI: 10.3390/biomedicines10040829.


Systemic MCPIP1 deficiency in mice impairs lipid homeostasis.

Moody J, Yang C, Sedinkin J, Chang Y Curr Res Pharmacol Drug Discov. 2021; 1:1-9.

PMID: 34909637 PMC: 8663940. DOI: 10.1016/j.crphar.2020.03.001.


Are non-high-density lipoprotein fractions associated with pediatric metabolic syndrome? The CASPIAN-V study.

Angoorani P, Khademian M, Ejtahed H, Heshmat R, Motlagh M, Vafaeenia M Lipids Health Dis. 2018; 17(1):257.

PMID: 30428934 PMC: 6236929. DOI: 10.1186/s12944-018-0895-1.